© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses questions still surrounding the optimal duration of pertuzumab (Perjeta) treatment for patients with HER2-positive breast cancer.